SEARCH

SEARCH BY CITATION

References

  • 1
    Liaw PC, Esmon CT, Kahnamoui K, Schmidt S, Kahnamoui S, Ferrell G, Beaudin S, Julian JA, Weitz JI, Crowther M, Loeb M, Cook D. Patients with severe sepsis vary markedly in their ability to generate activated protein C. Blood 2004; 104: 395864.
  • 2
    Carraway MS, Welty-Wolf KE, Miller DL, Ortel TL, Idell S, Ghio AJ, Petersen LC, Piantadosi CA. Blockade of tissue factor: treatment for organ injury in established sepsis. Am J Respir Crit Care Med 2003; 167: 12009.
  • 3
    Crawley J, Lupu F, Westmuckett AD, Severs NJ, Kakkar VV, Lupu C. Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels. Arterioscler Thromb Vasc Biol 2000; 20: 136273.
  • 4
    Gregory SA, Morrissey JH, Edgington TS. Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin. Mol Cell Biol 1989; 9: 27525.
  • 5
    Crossman DC, Carr DP, Tuddenham EG, Pearson JD, McVey JH. The regulation of tissue factor mRNA in human endothelial cells in response to endotoxin or phorbol ester. J Biol Chem 1990; 265: 97827.
  • 6
    Tang H, Ivanciu L, Popescu N, Peer G, Hack E, Lupu C, Taylor FB Jr, Lupu F. Sepsis-induced coagulation in the baboon lung is associated with decreased tissue factor pathway inhibitor. Am J Pathol 2007; 171: 106677.
  • 7
    Gando S, Kameue T, Morimoto Y, Matsuda N, Hayakawa M, Kemotsu O. Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis. Crit Care Med 2002; 30: 172934.
  • 8
    Stalboerger PG, Panetta CJ, Simari RD, Caplice NM. Plasmin proteolysis of endothelial cell and vessel wall associated tissue factor pathway inhibitor. Thromb Haemost 2001; 86: 9238.
  • 9
    Li A, Wun TC. Proteolysis of tissue factor pathway inhibitor (TFPI) by plasmin: effect on TFPI activity. Thromb Haemost 1998; 80: 4237.
  • 10
    Ott I, Malcouvier V, Schomig A, Neumann FJ. Proteolysis of tissue factor pathway inhibitor-1 by thrombolysis in acute myocardial infarction. Circulation 2002; 105: 27981.
  • 11
    Kothari H, Kaur G, Sahoo S, Idell S, Rao LV, Pendurthi U. Plasmin enhances cell surface tissue factor activity in mesothelial and endothelial cells. J Thromb Haemost 2009; 7: 12131.
  • 12
    Higuchi DA, Wun TC, Likert KM, Broze GJ Jr. The effect of leukocyte elastase on tissue factor pathway inhibitor. Blood 1992; 79: 171219.
  • 13
    Massberg S, Grahl L, von Bruehl ML, Manukyan D, Pfeiler S, Goosmann C, Brinkmann V, Lorenz M, Bidzhekov K, Khandagale AB, Konrad I, Kennerknecht E, Reges K, Holdenrieder S, Braun S, Reinhardt C, Spannagl M, Preissner KT, Engelmann B. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med 2010; 16: 88796.
  • 14
    Yun TH, Cott JE, Tapping RI, Slauch JM, Morrissey JH. Proteolytic inactivation of tissue factor pathway inhibitor by bacterial omptins. Blood 2009; 113: 113948.
  • 15
    Giles AR. Guidelines for the use of animals in biomedical research. Thromb Haemost 1987; 58: 107884.
  • 16
    Lupu C, Westmuckett AD, Peer G, Ivanciu L, Zhu H, Taylor FB Jr, Lupu F. Tissue factor-dependent coagulation is preferentially up-regulated within arterial branching areas in a baboon model of Escherichia coli sepsis. Am J Pathol 2005; 167: 116172.
  • 17
    Lijnen HR, van Hoef B, Lupu F, Moons L, Carmeliet P, Collen D. Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler Thromb Vasc Biol 1998; 18: 103545.
  • 18
    Declerck PJ, Verstreken M, Collen D. Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice. Thromb Haemost 1995; 74: 13059.
  • 19
    de Boer JP, Creasy AA, Chang A, Roem D, Brouwer MC, Eerenberg AJ, Hack CE, Taylor FB Jr. Activation patterns of coagulation and fibrinolysis in baboons following infusion with lethal or sublethal dose of Escherichia coli. Circ Shock 1993; 39: 5967.
  • 20
    Renckens R, Weijer S, de Vos AF, Pater JM, Meijers JC, Hack CE, Levi M, van der Poll T. Inhibition of plasmin activity by tranexamic acid does not influence inflammatory pathways during human endotoxemia. Arterioscler Thromb Vasc Biol 2004; 24: 4838.
  • 21
    de Jonge E, Dekkers PE, Creasey AA, Hack CE, Paulson SK, Karim A, Kesecioglu J, Levi M, van Deventer SJ, van der Poll T. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 2000; 95: 11249.
  • 22
    Taylor FB Jr. Staging of the pathophysiologic responses of the primate microvasculature to Escherichia coli and endotoxin: examination of the elements of the compensated response and their links to the corresponding uncompensated lethal variants. Crit Care Med 2001; 29: S7889.
  • 23
    Pajkrt D, van der Poll T, Levi M, Cutler DL, Affrime MB, van den Ende A, ten Cate JW, van Deventer SJ. Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemia. Blood 1997; 89: 27015.
  • 24
    Emeis JJ, van den Eijnden-Schrauwen Y, van den Hoogen CM, de Priester W, Westmuckett A, Lupu F. An endothelial storage granule for tissue-type plasminogen activator. J Cell Biol 1997; 139: 24556.
  • 25
    Bugge TH, Flick MJ, Daugherty CC, Degen JL. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 1995; 9: 794807.
  • 26
    Basavaraj MG, Gruber FX, Sovershaev M, Appelbom HI, Osterud B, Petersen LC, Hansen JB. The role of TFPI in regulation of TF-induced thrombogenicity on the surface of human monocytes. Thromb Res 2010; 126: 41825.
  • 27
    Shimokawa T, Yamamoto K, Kojima T, Saito H. Down-regulation of murine tissue factor pathway inhibitor mRNA by endotoxin and tumor necrosis factor-alpha in vitro and in vivo. Thromb Res 2000; 100: 21121.
  • 28
    Wilson SH, Bell MR, Rihal CS, Bailey KR, Holmes DR Jr, Berger PB. Infarct artery reocclusion after primary angioplasty, stent placement, and thrombolytic therapy for acute myocardial infarction. Am Heart J 2001; 141: 70410.